Journey Medical Corporation (NASDAQ:DERM) Receives $13.00 Average Target Price from Brokerages
by Jessica Moore · The Cerbat GemShares of Journey Medical Corporation (NASDAQ:DERM – Get Free Report) have been given a consensus recommendation of “Hold” by the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $13.00.
Several brokerages have recently weighed in on DERM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Journey Medical in a report on Thursday, March 26th.
Get Our Latest Stock Analysis on Journey Medical
Journey Medical Price Performance
DERM opened at $4.95 on Wednesday. Journey Medical has a 12 month low of $4.31 and a 12 month high of $9.56. The company has a market cap of $135.28 million, a PE ratio of -10.53 and a beta of 1.03. The company has a current ratio of 1.79, a quick ratio of 1.53 and a debt-to-equity ratio of 0.79. The company has a 50 day moving average of $7.53 and a 200 day moving average of $7.70.
Journey Medical (NASDAQ:DERM – Get Free Report) last issued its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $16.08 million for the quarter, compared to analysts’ expectations of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%. On average, sell-side analysts expect that Journey Medical will post -1.02 EPS for the current year.
Institutional Investors Weigh In On Journey Medical
A number of institutional investors and hedge funds have recently modified their holdings of the company. Police & Firemen s Retirement System of New Jersey purchased a new position in Journey Medical during the second quarter valued at approximately $29,000. Bank of America Corp DE lifted its stake in Journey Medical by 4,707.0% in the 2nd quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after purchasing an additional 4,048 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Journey Medical in the 2nd quarter worth approximately $36,000. JPMorgan Chase & Co. bought a new position in Journey Medical in the 2nd quarter valued at $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Journey Medical in the 2nd quarter valued at $48,000. 7.25% of the stock is owned by hedge funds and other institutional investors.
Journey Medical Company Profile
Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.
The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.